NUTXNutex Health Inc.

$209.37+117% 1Y

Is the price fair?

Good

Undemanding: modest expectations priced in and cheap vs its sector.

2 good, 1 without data
What the price assumes~−13% a year

Priced for a decline (~−13% a year). The price demands less than its three-year revenue growth of 62% a year, expectations look modest.

Vs sector (EV/EBIT)3.5×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

All from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)top 5% of the market
FCF yieldtop 3% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What NUTX's price assumes

Nutex Health Inc. trades at 8.29× earnings against 20.2× for the median Medical Care Facilities name, cheaper than its own group.

8.29

Trailing P/E · Medical Care Facilities median 20.2 · cheaper than the typical name in its group

Price / sales
1.69

Price / sales · today's price, trailing year to Jun 30, 2026

Free cash flow yield
19%

Free cash flow yield · Medical Care Facilities median 6.0%

Growth the price implies
−13%

Growth the price implies · The price pays for −13% free cash flow growth a year for a decade; revenue has grown 62% a year over the last three.

Details›
Price / booktoday's price, trailing year to Jun 30, 2026
3.64
EV / EBITtoday's price, trailing year to Jun 30, 2026
3.54
EV / salestoday's price, trailing year to Jun 30, 2026
1.52
Healthcare median P/E503 names
27.9
Medical Care Facilities median P/E32 names
20.2
Free cash flow, trailing twelve months
$274M
Market capitalisation6.8 million shares, counted Aug 4, 2026
$1.43B
3-year revenue growth
+62%

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

What is it worth?

Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.

Against its own past

Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.